Objective. To test the feasibility, acceptability, and effects of a home-based morning versus evening bright light treatment on function and pain sensitivity in women with fibromyalgia.
Introduction
Fibromyalgia is characterized by chronic widespread pain, affect/sleep disturbance, fatigue, and cognitive dysfunction [1] . People with fibromyalgia report high distress, disability, lost productivity, and poor quality of life [2] . Estimates suggest that fibromyalgia affects more than 20 million Americans [3] . Antidepressants, antiepileptic, and opioid analgesic medications have been tested, but findings indicate only small effects [4] [5] [6] with a high rate of dropout due to adverse side effects [4] . Cognitive behavioral therapy (CBT) and exercise also yield only small to modest effects [7] [8] [9] . Notably, exercise requires high participant motivation and CBT requires specialized personnel. Thus, there is a need to develop adjunctive approaches to manage fibromyalgia symptoms that have optimal treatment effects, minimal side effects, are readily available and affordable, and are easily implemented by participants without extensive support from specialized personnel.
Later circadian timing may be a modifiable risk factor for fibromyalgia symptoms, although this possibility remains to be fully investigated. For example, people with fibromyalgia who report later sleep times (a proxy marker of later circadian timing) also report significantly greater pain, even after controlling for age, sex, and employment [10] . Indeed, circadian timing could influence pain directly via central circadian afferents to the amygdala, a key pain center [11, 12] .
The purposes of this pilot study were to gather evidence on the feasibility and acceptability of bright light treatment for women with fibromyalgia and to test the effects of morning versus evening bright light. Bright light treatment consists of receiving high intensity UV-free light, most typically from a nearby light box. Our hypotheses were: 1) morning light treatment (1 hour/day for 6 days to phase advance or shift circadian timing earlier) would lead to greater improvements in function and pain sensitivity than evening light treatment (1 hour/day for 6 days to phase delay or shift circadian timing later); and 2) circadian phase advances (shift earlier) would be associated with greater improvements in function and pain sensitivity.
Methods

Participants
Ten women who reported a previous diagnosis of fibromyalgia and met the American College of Rheumatology (ACR)'s diagnostic criteria for fibromyalgia were enrolled in the study. The 2010 ACR criteria include that no other disorder is present to explain the pain (normal complete blood count and either normal erythrocyte sedimentation rate or C-reactive protein), the symptoms have been present for 3 months, and the pain is sufficiently widespread (widespread pain index, WPI) and severe (symptom severity, SS) (ACR criteria WPI 7 and SS 5 or WPI ¼ 3-6 and SS 9) [1] . Baseline characteristics of the sample are shown in Table 1 . All participants reported no other significant chronic disease, no past or present psychosis, bipolar disorder, or acute suicidal ideation, no retinal pathology, or eye surgery, and none were taking photosensitizing medications. Eight participants passed a urine drug screen for common drugs for abuse, one participant tested positive for opiates and benzodiapezenes (she later withdrew from study, see below), and another participant tested positive for benzodiapezenes. No participants had worked any night shifts nor travelled across more than two time zones in the month preceding the study. No participants had any prior experience with bright light treatment. No participants were color blind as determined from the Ishihara test. The study was approved by the Rush University Medical Center Institutional Review Board, and all participants gave written informed consent prior to participation.
Protocol
Total study duration was 15 days, and began with a 7-day baseline where participants slept at home on their usual sleep schedule (ad lib). Participants then visited the Sleep Center at Rush University Medical Center 12 hours before their habitual bedtime for a baseline assessment of their function (Fibromyalgia Impact Questionnaire, FIQ [13] ), pain sensitivity (details below), circadian timing (details below) and nighttime sleep (details below). The next day, HJB and a research assistant visited the participants at home to set up and instruct them on a 1 hour/day bright light treatment. After 6 days of self-administered bright light at home, participants returned to the Sleep Center for a reassessment of their function, pain sensitivity, and circadian timing. Both pre and post-treatment assessments occurred at the same time of day.
Five participants (#'s participant 1, 3, 5, 8, 9) were randomized to evening bright light, and five participants (#'s participant 2, 4, 6, 7, 10) were randomized to morning bright light. One participant (# participant 3) completed only the first two nights of evening bright light before withdrawing due to a work conflict with the second overnight stay in the Sleep Center. One participant (# participant 9) completed the evening bright light treatment, followed by the morning bright light treatment after a 2-week washout. However, due to potential carryover effects of the first treatment, this patient's second treatment was not included in the analysis. Thus, there was complete data from four evening light and five morning light participants.
Test of Pain Sensitivity
Pain sensitivity was assessed using a heat pain stimulus administered via a Medoc TSAII NeuroSensory Analyzer (Medoc US, Minneapolis, MN). The heating surface of the thermode was 3 cm x 3 cm. An ascending method of limits protocol was used [14] . Four trials were conducted for pain threshold and tolerance, with each trial conducted sequentially at one of four different nonoverlapping sites on the non-dominant ventral forearm. An interval of 30 secs between successive stimuli was used. For pain threshold trials, the probe started at an adaptation temperature of 32 C, with temperature increasing at a ramp rate of 0.5 C/sec until the participant indicated that the stimulus had begun to feel "painful." For each tolerance trial, the probe started at an adaptation temperature of 40 C, with temperature increasing at a ramp rate of 0.5 C/sec until the participant indicated tolerance. Means of the four heat pain threshold and tolerance trials were separately derived.
Circadian Phase Assessments
Participants were prompted by phone calls to refrain from consuming non-steriodal anti-inflammatory drugs (NSAIDs) 72 hours before, and alcohol/caffeine 24 hours before the overnight stays in the Sleep Center, to avoid affecting the measurement of melatonin. Acetaminophen was provided if needed. Participants were breathalyzed upon arrival to ensure they had not recently consumed alcohol. During the phase assessments, participants remained awake and seated in dim light (<5 lux, Extech 403125 light meter, Nashua, NH, USA) and were continuously monitored by staff. After 30 minutes in the dim light, participants gave a saliva sample every 30 minutes using Salivettes (Sarstedt, Newton, NC). During the baseline phase assessment, sampling started 6 hours prior to average bedtime and continued until average bedtime. In the final phase assessment, saliva sampling started 3 hours earlier or extended to 3 hours later to capture expected phase shifts. Neither toothpaste nor mouthwash were allowed during the phase assessments. Small snacks and fluids were permitted, except in the 10 minutes before each sample, and participants were required to rinse and brush their teeth with water while remaining seated 10 minutes before each sample if they had consumed food or drink. The samples were centrifuged immediately upon collection and frozen. The samples were later shipped in dry ice to Solidphase Inc. (Portland, ME), which radioimmunoassayed the samples for melatonin using commercially available kits (ALPCO, Inc., Salem, NH). The assay sensitivity was 0.5 pg/ml intra-assay and inter-assay coefficients of variation for low levels of salivary melatonin are 20.1%, and 16.7%, respectively. A dim light melatonin onset (DLMO) was calculated for each phase assessment as the clock time (with linear interpolation) when the melatonin concentration exceeded the mean of 3 low consecutive daytime values plus twice the standard deviation of these points [15, 16] . The DLMO is a reliable marker of human circadian timing [17, 18] . Circadian phase shifts were calculated as the difference between the baseline DLMO and the final DLMO.
Polysomnography
All participants completed a standard clinical polysomnography (PSG) evaluation during their first overnight stay in the Sleep Center. The technician-monitored PSG included 19 channels for EEG, EOG, chin, and bilateral anterior tibialis EMG, EKG, snoring, airflow, respiratory effort, and pulse oximetry. The sleep recordings were scored by a registered polysomnographic technologist according to standard procedures [19] , and reviewed by MP who discussed the results with each participant, including a referral for treatment if required. Each participant's sleep episode was timed to match their average sleep schedule.
Bright Light Treatment at Home
On arrival at each participant's home after the first overnight stay in the Sleep Center, HJB and a research assistant discussed with the participant their preferred activity during the light treatment (e.g., watching TV, reading, etc). Two commercially available broadspectrum white light boxes (33 x 18 x 55 cm, EnergyLight HF3318/60, Philips, Inc) were set up slightly to the left and right to allow the participant to view a TV or computer in front of them ( Figure 1 ). Each participant's comfort was first maximized using comfortable chairs and/or cushions as appropriate, and then the light boxes were positioned to maximize light intensity (Extech EA33 light meter, Nashua, NH, >3,000 lux). A 1 hour light pulse of this intensity is bright enough to significantly shift circadian timing [20] . A 60 cm string was taped to the base of each light box to remind the participants how close they needed to sit near the light boxes, and painter's tape was placed around the base of each light box to show where the boxes should remain. The morning light treatment was for 1 hour/day for 6 days, and started each morning at the participant's average wake time. The evening light treatment was for 1 hour/day for 6 days, and started 1 hour before average bedtime, and ended at average bedtime. A photosensor (Actiwatch Spectrum, Philips, Inc) was taped facing inwards to the outside of each light box to confirm compliance. An alarm clock was set to the start of the bright light treatment and was placed near the light boxes (participants also set their home alarm clock). Participants were given a list of written reminders including: 1) adjust each light box to provide maximum illumination, 2) not permit family/friends to touch the light boxes, 3) only turn on light boxes during the scheduled time, and 4) turn on all ambient lighting during light treatment time. At the end of the light set up, participants completed a treatment expectation item of 1 "expect to be completely pain free" to 7 "expect no change". Research staff also called each participant daily, shortly after the start of the light treatment to confirm correct use of the light boxes, and assess potential side effects. Figure 1 A research staff member sitting on a participant's couch after the light boxes were set up. Two light boxes were used: one light box was positioned slightly to the left and one light box slightly to the right so that the participant could watch TV between them.
Light Treatment for Fibromyalgia
Statistical Analysis
Simple change scores were computed by subtracting baseline from post-treatment values. Due to the small sample size, Mann-Whitney U tests were used to test differences between the morning light and evening light treatment groups on baseline to post-treatment changes in FIQ scores, pain threshold, and tolerance. Spearman correlations were calculated to examine relationships between circadian timing (DLMO) and function and pain sensitivity change scores. Statistical significance for all analyses was determined with two-tailed tests at P < 0.05.
Results
At baseline, all 10 participants had FIQ scores >50 and two participants scored >70 indicating severe symptoms [13] (Table 1) . We noted during the home visits that seven of the 10 participants kept their homes dimly lit, as they had covered all windows to avoid exposure to outside light, consistent with reports of photophobia in fibromyalgia [21] . All participants had similar treatment expectations (rated 2-4 on 1 "expect to be completely pain free" to 7 "expect no change"), suggesting that they were unaware morning bright light was hypothesized to be more effective than evening bright light. Data from the photosensors on the light boxes indicated that on average the participants received bright light during 84% of the scheduled light treatment times (range 56.7-99.7%). No participant reported any side effects or adverse events associated with either light treatment.
The direction of effects suggested that participants in the morning light group experienced greater baseline to post-treatment changes in FIQ scores, pain threshold, and tolerance than participants in the evening bright light group (Figure 2 ). The comparison for FIQ scores did not reach statistical significance (Mann-Whitney U ¼ 4.00; P ¼ 0.14) but the average reduction in FIQ scores from baseline was 24% in the morning light group and only 12% in the evening light group. Accordingly, the magnitude of the reduction in FIQ scores was only clinically meaningful in the morning light group [22] . Participants in the morning light group showed a significantly greater increase in pain threshold than the evening light group (Mann-Whitney U ¼ 2.00; P < 0.05), but this comparison was not significant for pain tolerance (Mann-Whitney U ¼ 5.00; P ¼ 0.22).
All participants who received evening light phase delayed their dim light melatonin onset (between 1.4-2.4 h), whereas all participants who received morning light phase advanced their DLMO (between 0.1-1.5 h); these findings are comparable to phase shifts reported previously for 1 hour light treatments either before habitual bedtime or after habitual wake time [23] . The smallest phase advance (0.1 h) occurred in a participant who napped immediately after the morning bright light, and this "dark pulse" likely countered the effect of the morning light. Spearman correlation coefficients were generated between baseline to post-treatment changes in FIQ scores, pain threshold, and tolerance, and the shift in DLMO. Results are shown in Figure 3 . Larger phase advances were associated with greater improvements on the FIQ, but the effect was nonsignificant Figure 2 The individual changes in Fibromyalgia Impact Questionnaire (FIQ), heat threshold, and heat tolerance from baseline to after the 6-day morning and evening light treatments. Means and standard deviations for each treatment group are shown.
(r s ¼ 0.47, P ¼ 0.21). Larger phase advances were significantly associated with greater increases in pain tolerance (r s ¼ 0.67, P ¼ 0.05), and there was a nonsignificant trend for greater increases in pain threshold (r s ¼ 0.63, P ¼ 0.067).
One major purpose of this pilot feasibility study was to estimate the sample size necessary to allow for meaningful and robust conclusions so as to inform the design of a future randomized controlled trial. For the purpose of this analysis, we designated FIQ changes from baseline to post-treatment as the main outcome. We calculated the effect size for FIQ changes between the evening and morning light groups, which was Cohen's d ¼ 0.974. Thus, with power at 0.95, P < 0.05, the effect size at d ¼ 0.974, we would need 29 subjects per group to have a 95% chance of finding a significant effect.
Discussion
Our ability to recruit participants and to retain all but one in this treatment protocol suggests that bright light treatment for women with fibromyalgia is both a feasible adjunctive treatment and is acceptable to participants. Further, results of this pilot study suggest that women with fibromyalgia who undergo morning bright light treatment may show greater improvements in pain sensitivity and function than those who undergo evening bright light treatment.
Although the reductions in FIQ scores following morning light treatment (14.1 points) were not significantly greater than FIQ changes following evening light treatment (7.9 points), the magnitude of change reported by the morning light participants is large enough to be considered clinically meaningful. Indeed, the reduction in FIQ scores following the morning light treatment exceeded a 14% reduction from baseline, suggesting clinical relevance [22] . Furthermore, the decrease in FIQ scores is comparable to those reported in trials of CBT for fibromyalgia [e.g., 7.7 points [24] and 8.7 points [25] . This improvement in fibromyalgia symptoms after only 6 days of morning bright light treatment also represents more than half of the average gains reported after 8-21 weeks of exercise training (16.75 reduction in FIQ scores [9] , with the latter intervention requiring substantial participant motivation. A recent 12-session 6-week multidisciplinary treatment for fibromyalgia, including CBT and exercise, showed an average 14 point reduction in FIQ [26] .
Findings also suggest that pain sensitivity may be decreased with morning light treatment. Apart from pain intensity rooted in fibromyalgia symptoms, pain sensitivity reveals the magnitude of a stimulus when it is first sensed as painful, and then when it becomes intolerable. Reductions in pain sensitivity could be as clinically meaningful as reductions in fibromyalgia pain intensity because reductions in the former could signal decreased vulnerability to pain flares, and sensations accompanying physical activity or physical touch. These results also suggest that morning light treatment effects were manifested in both changes in self-report -FIQ scores -and pain sensitivity -pain threshold and tolerance -measures; assessments using two distinct assessment methods. From the standpoint of feasibility and acceptability, participants reported no adverse effects to the light treatments and, apart from one scheduling conflict, all participants successfully completed each treatment. These findings are consistent with reports that only occasional side effects are associated with light treatment, such as headache, eyestrain, nausea, and agitation [27] , but that even when these effects occur, these symptoms often remit spontaneously [27, 28] , and participants rarely discontinue treatment due to such side effects [28] . Importantly, bright light devices (with UV filter) are safe, with no changes in extensive ophthalmologic examination observed after up to 6 years of daily use (in fall and winter) [29] . Further, participants reported enthusiasm for a non-pharmacological intervention that they could self-administer in their home, and improvements in function and pain sensitivity were observed despite the presence or absence of multiple medications and sleep apnea. Thus, it appears that women with fibromyalgia may be willing and able to engage in bright light therapy.
There were limitations to this study. Clearly, the sample size was small and the findings should be considered preliminary. The study was only single-blinded due to the staff being aware of whether participants received morning or evening bright light. However, staff were instructed not to discuss possible treatment outcomes with the participants. As treatment expectations were similar between the two groups, placebo effects were likely similar between them as well. We note that circadian timing could also influence pain indirectly via its significant influence on affect and sleep [30] [31] [32] , which in turn can influence fibromyalgia pain [33, 34] . Therefore, future work should comprehensively assess mood and sleep before and after light treatment. Finally, longer durations of light treatment (greater than 6 days) may lead to even larger improvements in function and pain sensitivity.
Conclusions
The results from this proof of concept pilot study suggest that a home-based morning bright light treatment, 1 hour/day, starting at habitual wake time, is a feasible treatment protocol and may improve function and reduce pain sensitivity in participants with fibromyalgia.
